Handelsbanken Fonder Ab Apellis Pharmaceuticals, Inc. Transaction History
Handelsbanken Fonder Ab
- $26.2 Billion
- Q4 2024
A detailed history of Handelsbanken Fonder Ab transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 30,600 shares of APLS stock, worth $873,018. This represents 0.0% of its overall portfolio holdings.
Number of Shares
30,600
Previous 27,600
10.87%
Holding current value
$873,018
Previous $796,000
22.61%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
113MCall Options Held
3.85MPut Options Held
1.09M-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$339 Million14.88% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$337 Million0.07% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$317 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$287 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$165 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.13B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...